myFINACEA.com

IMPORTANT SAFETY INFORMATION ABOUT FINACEA^®

FINACEA is the first and only gel approved by the FDA to treat the bumps, pimples, and associated redness of mild to moderate rosacea.

The active ingredient of FINACEA is naturally occurring

FINACEA contains azelaic acid (AzA), a naturally occurring ingredient. It comes in a water-based gel free of fragrance or alcohol and helps to limit allergic reaction and dryness

November 2010 eNewsletter

Beyond Skin Basics Rosacea at night

Going undercover

Winter is all about staying warm: wool scarves, heavy coats, feather duvets, and electric blankets. If you're wondering whether you have to choose between flare–ups and freezing – you don't.
There are ways to stay comfortable once you´ve crawled underneath the covers.
Pillow talk

You've lowered the thermostat, put away your flannel pajamas, and traded in your down quilt for a cotton comforter. You've done everything you can to prevent overheating. Or have you?
Here are some proactive steps you can take to keep your cool.

VIEW PAST ARTICLES

| VIEW FULL NEWSLETTER

FINACEA is here to help

Receive emails with important info that will help you take control of managing your rosacea along with occasional promotions!

A quick, convenient routine to help you take control of managing your rosacea.

LEARN MORE

Already using FINACEA?

INDICATIONS & USAGE

FINACEA is indicated for topical treatment of inflammatory papules and pustules of mild to moderate rosacea. Although some reduction of erythema, which was present in patients with papules and pustules of rosacea, occurred in clinical studies, efficacy for treatment of erythema in rosacea in the absence of papules and pustules has not been evaluated.

IMPORTANT SAFETY INFORMATION

FINACEA is for dermatologic use only, and not for ophthalmic, oral, or intravaginal use. FINACEA is contraindicated in individuals with a history of hypersensitivity to propylene glycol or any other component of the formulation. In clinical trials, sensations of burning/stinging/tingling occurred in 29% of patients, and itching in 11%, regardless of the relationship to therapy. Post-marketing safety - Skin: facial burning and irritation; Eyes: iridocyclitis on accidental exposure to the eye. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with a dark complexion, these patients should be monitored for early signs of hypopigmentation.

Other than FINACEA, Intendis, Inc. (part of the Bayer group) does not promote or endorse any products or recommendations made by third parties. All products and brand names listed are the property and responsibility of their respective trademark and copyright holders.

Please see full prescribing information for FINACEA.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION ABOUT FINACEA®